The Case for Negotiation Skills in Pharma: Why Market Access Teams Need to Rethink the Payer Conversation

Regulatory approval is the first hurdle, but after that, the harder commercial question begins: how do you secure access in a market where payers are under pressure, evidence is being scrutinised more closely, and pricing decisions are increasingly visible? For market access and pricing and reimbursement teams, the challenge is not only to make a compelling case for value, but to negotiate how that value will be recognised, funded and managed in a healthcare system with limited room to move.

Drawing from our experience over 50 years helping a wide range of pharma organisations develop long lasting negotiation skills, let’s highlight the key issues we’ve seen first hand that Market Access teams struggle with, and how developing negotiation skills can help not only speed up the long Payer process, but also build value on the road to success with Payers.

Main challenges faced by Market Access teams

1. The access environment is getting tighter

Across Europe, access delays remain a persistent problem. EFPIA’s 2025 Patients W.A.I.T. Indicator found that the median time to availability for new medicines across 36 European countries was 532 days, with major variation between markets. Germany recorded a median of 56 days, while Romania recorded 1,201 days. For pharma teams, this reinforces a familiar reality: a strong product and a positive authorisation do not create a straight path to patients. Availability still depends on local reimbursement processes, evidence expectations, pricing discussions and system-level affordability.

In the US, the Medicare Drug Price Negotiation Program has brought selected high-expenditure medicines into a formal government-led negotiation process. CMS states that the first ten selected Medicare Part D drugs were negotiated for initial price applicability year 2026, with maximum fair prices due to take effect from 1 January 2026. Whatever view companies take on the policy, it reflects a wider shift in the access environment: price, value and affordability are being scrutinised in a more structured and public way.

2. Market Access teams are operating in an increasingly complex and evolving HTA and Payer landscape

The EU Health Technology Assessment Regulation adds another layer of complexity. From January 2025, new cancer medicines and advanced therapy medicinal products became subject to joint clinical assessments at EU level. The aim is to reduce duplication and support Member States with a shared clinical assessment, but companies still need to navigate national pricing and reimbursement decisions. That means access teams need a value narrative that can hold up across a more coordinated evidence process, while still being adaptable enough for local decision-making.

Importantly, this highlights the need for a stronger internal alignment on what the evidence supports, where uncertainty remains and particularly what trade-offs would be acceptable in different markets. If not handled well, these conversations could halt momentum before external negotiations even begin.

Teams need to make sure people entering payer discussions have a clear mandate. When priorities are unresolved internally, decisions get escalated late, messages become inconsistent and teams can lose time in access processes.

Stronger negotiation skills help identify internal tensions earlier: test assumptions, clarify priorities, agree decision ownership and prepare better on what can be traded, protected and accepted.

3. Stakeholders at national, regional and local levels have their own challenges and demands

Despite moves towards more coordinated assessment, European access remains highly uneven. GlobalData analysis reported significant variation in reimbursement of branded medicines approved since 2021, with the five major European markets reimbursing substantially more products than the broader European average. The UK and Germany each included 85% of those approved products in the analysis, while smaller markets such as Cyprus, Croatia and Lithuania reimbursed far lower proportions. For global and regional teams, this makes negotiation harder: the value story may be global, but the route to access is still local.

Successful teams will anticipate how different stakeholders will interpret value, where resistance is likely to come from and what kind of proposal will have better chances in each setting. A national payer may be focused on affordability and precedent. A regional decision-maker may be more concerned with implementation. A hospital or local procurement body may need confidence around patient eligibility, volume, supply or service support.

Rather than treating every objection as a challenge to the product’s value, teams should learn how to adapt without becoming reactive. They must learn to identify the pressure behind objections and shape the conversation accordingly. The better they understand each stakeholder’s pressures, priorities and decision criteria, the easier it becomes to keep the conversation moving. Negotiation skills help teams avoid repeated delays, unnecessary escalation and one-size-fits-all messaging, giving them a clearer route through local access conversations while still protecting the broader value strategy.

The biggest barrier: Overreliance on persuasion

This is where pharma negotiation skills development has a role to play, because high technical confidence can sometimes pull the conversation towards explanation rather than negotiation. A strong clinical and economic case is essential, but what are your teams doing if this approach doesn’t work the way they want? In our experience, we’ve seen Market Access teams miss opportunities because they have not uncovered where the flexibility lies with Payers, and have relied on one approach. A part of building negotiation skills is developing the need to be curious: teams need to ask better questions, test assumptions earlier, and understand what would make an agreement workable from the payer’s side.

The strongest access negotiations will not rely on defending value harder, but creating a wider negotiable space. That means knowing which variables can be moved, which cannot, what the internal mandate really is, where evidence uncertainty can be shared or reduced, and what concessions would protect access without unnecessarily eroding long-term value. In a payer environment shaped by affordability pressure, HTA scrutiny and local variation, the quality of the negotiation skills matters as much as the strength of the value story.

Negotiation skills development should reflect the reality of access today

For experienced pharma teams involved in crucial value-building conversations with payers, technical expertise is essential. But in the current market access environment, it is not always enough.

Teams need to understand how they behave when value is challenged. Do they ask enough questions before making concessions? Do they know which variables are available to trade? Can they distinguish between a price objection, an evidence concern, a budget constraint and a broader access issue?

By understanding how teams currently negotiate, organisations can identify where value may be lost: through reactive discounting, unclear trade-offs, weak internal alignment, over-reliance on persuasion, or missed opportunities to shape access conditions more creatively.

Evidence still matters, but evidence does not negotiate by itself. Teams that combine technical expertise with stronger negotiation capability will be better placed to protect value, move through complex access processes and reach agreements that work for payers, patients and the organisation.